Magdalena Lewandowska

Magdalena Lewandowska

Auto-generated profile, based on publicly available information

Magdalena Lewandowska

Indiana Hemophilia and Thrombosis Center Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Open access
MLMagdalena Dorota Lewandowska
Magdalena Dorota Lewandowska
JCJean Marie Connors
Jean Marie Connors
Factor XI (FXI) deficiency (hemophilia C or Rosenthal disease) was first described in the 1950s in a multigenerational family experiencing bleeding related to surgery and dental procedures. Managing patients with FXI deficiency presents several challenges, including a lack of correlation of bleeding symptoms with FXI activity levels, the large volume of fresh frozen plasma required to achieve hemostatic FXI levels, lack of availability of FXI concentrate in certain regions of the world, and the inherent thrombotic risk associated with replacement therapy. This article summarizes presentation, diagnosis, and management of patients with FXI deficiency in a variety of clinical settings.

1 September 2023 in Science
Verified
Journal Article
Closed access
WDWen Dai
Wen Dai
HZHeng Zhang
Heng Zhang
HLHayley Lund
Hayley Lund
ZZZiyu Zhang
Ziyu Zhang
MCMark Castleberry
Mark Castleberry
ZZZe Zheng
Ze Zheng
Apolipoprotein B (apoB)–lipoproteins initiate and promote atherosclerotic cardiovascular disease. Plasma tissue plasminogen activator (tPA) activity is negatively associated with atherogenic apoB-lipoprotein cholesterol levels in humans, but the mechanisms are unknown. We found that tPA, partially through the lysine-binding site on its Kringle 2 domain, binds to the N terminus of apoB, blocking the interaction between apoB and microsomal triglyceride transfer protein (MTP) in hepatocytes, thereby reducing very-low-density lipoprotein (VLDL) assembly and plasma apoB-lipoprotein cholesterol levels. Plasminogen activator inhibitor 1 (PAI-1) sequesters tPA away from apoB and increases VLDL assembly. Humans with PAI-1 deficiency have smaller VLDL particles and lower plasma levels of apoB-lipoprotein cholesterol. These results suggest a mechanism that fine-tunes VLDL assembly by intracellular interactions among tPA, PAI-1, and apoB in hepatocytes.

27 November 2020 in Haemophilia
Verified
Journal Article
Open access
PDF file
MLMagdalena Lewandowska
Magdalena Lewandowska
NRNicole Randall
Nicole Randall
NBNihal Bakeer
Nihal Bakeer
JMJennifer Maahs
Jennifer Maahs
JSJeanne Sagar
Jeanne Sagar
ASAmy D. Shapiro
Amy D. Shapiro
Introduction Surgery is frequently required in persons with haemophilia A (PwHA). Emicizumab, a bispecific, humanized monoclonal antibody, bridges activated factor (F) IX and FX. Management of patients undergoing surgery while receiving emicizumab is of clinical interest due to paucity of data. Aim Review real‐world experience of PwHA with/without FVIII inhibitors who required surgery while receiving emicizumab prophylaxis. Methods Data regarding peri‐operative management, including type of surgery, haemostatic agent use and bleeding complications, were collected for PwHA receiving emicizumab undergoing surgery between 25/10/18 and 31/12/19 at the Indiana Hemophilia and Thrombosis Center. Analyses were exploratory and descriptive. Results Twenty minor and five major surgeries were performed in 17 and five patients, respectively. Overall, 9/20 minor surgeries were planned to occur with emicizumab as the sole haemostatic agent; of these, four required additional coagulation factor (2 due to haematomas following port removals, 1 due to oozing at port removal site, 1 due to bleeding following squamous cell carcinoma removal). Three of the 11 minor surgeries with planned additional coagulation factor resulted in non‐major bleeds; all were safely managed with additional coagulation factor. All five major surgeries were planned with additional haemostatic agents; there was 1 bleed in a patient undergoing elbow synovectomy with nerve transposition, likely triggered by physical/occupational therapy. There were no major bleeds, thrombotic events or deaths. Conclusions Additional haemostatic agent use is safe in PwHA undergoing surgery while receiving emicizumab. Additional data are needed to determine the optimal dosing/length of treatment of additional haemostatic agents to lower bleeding risk.

11 November 2022 in Haemophilia
Verified
Journal Article
Open access
XZXinruo Zhang
Xinruo Zhang
MLMagdalena Lewandowska
Magdalena Lewandowska
MAMolly Aldridge
Molly Aldridge
KIKristy Iglay
Kristy Iglay
EWEric Wolford
Eric Wolford
ASAmy Shapiro
Amy Shapiro
Introduction: Hereditary factor XI (FXI) deficiency is a rare coagulation disorder that may result in excessive bleeding requiring intervention to restore haemostasis.Aim: The aim of this review was to report the current knowledge of the worldwide incidence and prevalence of FXI deficiency.Methods: A targeted PubMed search using terms related to FXI deficiency was conducted to identify studies published from April 2002 through April 2022. A manual search supplemented the electronic search. Studies were eligible for data abstraction if they reported population‐based incidence proportions/rates or prevalence proportions for FXI deficiency.Results: The electronic and manual searches returned 253 publications. After applying exclusion criteria, seven publications were included in the analysis, including a global report from the World Federation of Haemophilia (WFH). Six publications provided information on the prevalence of FXI deficiency that included 74 countries and regions. The estimated prevalence of FXI in the WFH report ranged from 0/100,000 in several countries to 55.85/100,000 individuals in the United Kingdom. Prevalence estimates in the PubMed findings ranged from .1 to 246.2/1,000,000 inhabitants with varying methods of case identification and time periods of analysis. One study estimated the incidence of FXI deficiency in Yecla, Spain at 2% of blood donors and .09% of hospital inpatients/outpatients with activated partial thromboplastin time (aPTT) tests.Conclusion: FXI deficiency is rare across the world, but additional steps could be taken to improve incidence and prevalence estimation, for example, development of a consistent FXI deficiency definition and incorporating genetic testing into a clinical routine to better identify and characterise cases.

25 October 2025 in Haemophilia
Verified
Journal Article
Closed access
GPGlenn F Pierce
Glenn F Pierce
MOMargareth C Ozelo
Margareth C Ozelo
JMJohnny Ndoni Mahlangu
Johnny Ndoni Mahlangu
ADAmy L Dunn
Amy L Dunn
MBMarlene Beijlevelt
Marlene Beijlevelt
WPWfh Aav Gene Therapy Guidelines Expert Panel
Wfh Aav Gene Therapy Guidelines Expert Panel

4 March 2022 in Haemophilia
Verified
Journal Article
Closed access
CMConnie H. Miller
Connie H. Miller
JSJ. Michael Soucie
J. Michael Soucie
VBVanessa R. Byams
Vanessa R. Byams
APAmanda B. Payne
Amanda B. Payne
KAKaron Abe
Karon Abe
ASAmy D. Shapiro
Amy D. Shapiro